Benefits of Integrated Medicines, Nutrition and Training 

Introduction

Recent evidence indicates that anti‐obesity medications (especially GLP‐1 receptor agonists) produce large weight losses when added to standard care. A 2026 meta‐analysis of 21 RCTs (n≈7000) found that GLP‐1 agonists (e.g. semaglutide, tirzepatide) dramatically increased the odds of clinically significant weight loss versus placebo (78.5% vs 26.5% of patients lost any weight; OR ≈11.4) (1). These agents act by suppressing appetite and improving metabolic parameters, offering a breakthrough therapy for obesity. However, WHO and other guideline committees emphasize that medication alone is insufficient; obesity is chronic and multifactorial, demanding integrated care. The WHO 2023 guideline explicitly recommends long-term GLP-1 therapy coupled with intensive behavioral support (diet + exercise) to maximize and sustain benefits (2).

​

Discussion

Structured exercise programs yield additional benefit. A 2024 meta-analysis of 116 RCTs (∼6900 adults) showed that moderate-to-vigorous aerobic exercise (≥150 min/week) produced modest but clinically relevant reductions in weight, waist circumference, and body fat, roughly 0.5 kg extra loss over controls (3). More importantly, supervised training improves fitness and may help sustain weight loss. In a trial combining GLP-1 agonist (liraglutide) with a year of supervised exercise, participants maintained significantly more weight loss one year after stopping treatment than those on drug alone (5).

Finally, evidence-based dietary support is crucial. Multicomponent programs combining calorie-deficit diets with exercise lead to greater long-term weight loss than single modalities. A systematic review found that diet+exercise interventions achieved significantly more weight loss at 12 months than diet or exercise alone (4). Clinical guidelines likewise recommend structured, nutritionally balanced diets supervised by qualified professionals (dietitians) to help achieve and maintain energy deficits (4).

​

Conclusion

In summary, high-quality evidence supports a multidisciplinary model: combining pharmacotherapy (GLP-1 drugs) with supervised exercise and nutritional counseling yields superior weight management outcomes compared to any single intervention (2) (5).